Resultats globals: 3 registres trobats en 0.04 segons.
Articles, 3 registres trobats
Articles 3 registres trobats  
1.
10 p, 595.1 KB Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma / Wick, Antje (Heidelberg University Medical Center. Clinical Cooperation Unit Neuro-oncology, German Cancer Research Center) ; Desjardins, Annick (Duke University. The Preston Robert Tisch Brain Tumor Center at Duke) ; Suarez, Cristina (VHIO) ; Forsyth, Peter (H. Lee Moffitt Cancer Center and Research Institute) ; Gueorguieva, Ivelina (Eli Lilly and Company) ; Burkholder, Tiana (Eli Lilly and Company) ; Cleverly, Ann Louise (Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company) ; Wang, Shuaicheng (BioStat Solutions, Inc, Frederick, MD USA) ; Lahn, Michael M. (Eli Lilly and Company) ; Guba, Susan C. (Eli Lilly and Company) ; Capper, David (Department of Neuropathology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany) ; Rodon Ahnert, Jordi (VHIO) ; Universitat Autònoma de Barcelona
The online version of this article (10. 1007/s10637-020-00910-9) contains supplementary material, which is available to authorized users.
2020 - 10.1007/s10637-020-00910-9
Investigational New Drugs, Vol. 38 (march 2020) , p. 1570-1579  
2.
7 p, 1.3 MB Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer / Melisi, Davide (University of Verona, Piazzale Ludovico Antonio Scuro) ; Garcia-Carbonero, Rocio (Oncology Department, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), UCM, CNIO, CIBERONC, Madrid, Spain) ; Macarulla, Teresa (VHIO) ; Pezet, Denis (Centre Hospitalier Universitaire) ; Deplanque, Gael (Hôpital Riviera-Chablais) ; Fuchs, Martin (Klinikum Bogenhausen, Städtisches Klinikum München GmbH, Englschalkinger Road 77, 81925 Munich, Germany) ; Trojan, Jorg (Goethe University Medical Center) ; Oettle, Helmut (Onkologische und Hämatologische Schwerpunktpraxis, Friedrichshafen, Germany) ; Kozloff, Mark (Ingalls Memorial Hospital) ; Cleverly, Ann (Eli Lilly and Company, Erl Wood Manor, Windlesham) ; Smith, Claire (formerly of Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company, Lilly Corporate Center) ; Gueorguieva, Ivelina (Eli Lilly and Company, Erl Wood Manor, Windlesham) ; Lahn, Michael M. F. (Wisconsin Ave., #8008, Bethesda, MD 20815 USA) ; Blunt, Al (Advaxis, Inc) ; Benhadji, Karim A. (Eli Lilly and Company) ; Tabernero, Josep (Universitat Autònoma de Barcelona. Departament de Medicina) ; Universitat Autònoma de Barcelona
Galunisertib is the first-in-class, first-in-human, oral small-molecule type I transforming growth factor-beta receptor (ALK5) serine/threonine kinase inhibitor to enter clinical development. The effect of galunisertib vs. [...]
2018 - 10.1038/s41416-018-0246-z
British Journal of Cancer, Vol. 119 (october 2018) , p. 1208-1214  
3.
14 p, 1.9 MB Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer / Rodón, Jordi (Hospital Universitari Vall d'Hebron) ; Carducci, Michael (Johns Hopkins Kimmel Cancer Center) ; Sepulveda-Sánchez, Juan M. (Hospital Universitario 12 de Octubre) ; Azaro, Analía (Hospital Universitari Vall d'Hebron) ; Calvo, Emiliano (START Madrid, Centro Integral Oncológico Clara Campal) ; Seoane, Joan (Hospital Universitari Vall d'Hebron) ; Braña, Irene (Hospital Universitari Vall d'Hebron) ; Sicart, Elisabet (Hospital Universitari Vall d'Hebron) ; Gueorguieva, Ivelina (Eli Lilly and Company) ; Cleverly, Ann (Eli Lilly and Company) ; Pillay, N. Sokalingum (Eli Lilly and Company) ; Desaiah, Durisala (Eli Lilly and Company) ; Estrem, Shawn T. (Eli Lilly and Company) ; Paz-Ares, Luis (Hospital Virgen del Rocío, Sevilla, Spain) ; Holdhoff, Matthias (Johns Hopkins Kimmel Cancer Center) ; Blakeley, Jaishri (Johns Hopkins University) ; Lahn, Michael M. (Eli Lilly and Company) ; Baselga Torres, Josep, 1959-2021, (Hospital Universitari Vall d'Hebron) ; Universitat Autònoma de Barcelona
Purpose Transforming growth factor-beta (TGF-β) signaling plays a key role in epithelial-mesenchymal transition (EMT) of tumors, including malignant glioma. Small molecule inhibitors (SMI) blocking TGF-β signaling reverse EMT and arrest tumor progression. [...]
2014 - 10.1007/s10637-014-0192-4
Investigational New Drugs, Vol. 33 (december 2014) , p. 357-370  

Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.